TrialPloS one2017

Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.

Valeria Cento et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.